These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34716713)

  • 21. The Immunomodulatory Properties of the Human Amnion-Derived Mesenchymal Stromal/Stem Cells Are Induced by INF-γ Produced by Activated Lymphomonocytes and Are Mediated by Cell-To-Cell Contact and Soluble Factors.
    Bulati M; Miceli V; Gallo A; Amico G; Carcione C; Pampalone M; Conaldi PG
    Front Immunol; 2020; 11():54. PubMed ID: 32117234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Stromal Cell Conditioned Medium and Antipurinergic Treatment on Macrophage Phenotype.
    Arabiyat AS; Yeisley DJ; Güiza-Argüello VR; Qureshi F; Culibrk RA; Hahn J; Hahn MS
    Tissue Eng Part C Methods; 2022 Dec; 28(12):656-671. PubMed ID: 36329666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional Profiling of Chondrogenically Induced Multipotent Stromal Cell Aggregates Reveals Transcriptomic and Emergent Morphological Phenotypes Predictive of Differentiation Capacity.
    Lam J; Bellayr IH; Marklein RA; Bauer SR; Puri RK; Sung KE
    Stem Cells Transl Med; 2018 Sep; 7(9):664-675. PubMed ID: 30084545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells.
    Hegyi B; Kudlik G; Monostori E; Uher F
    Biochem Biophys Res Commun; 2012 Mar; 419(2):215-20. PubMed ID: 22333568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1.
    Sheng H; Wang Y; Jin Y; Zhang Q; Zhang Y; Wang L; Shen B; Yin S; Liu W; Cui L; Li N
    Cell Res; 2008 Aug; 18(8):846-57. PubMed ID: 18607390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.
    English K; Barry FP; Field-Corbett CP; Mahon BP
    Immunol Lett; 2007 Jun; 110(2):91-100. PubMed ID: 17507101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially.
    Prasanna SJ; Gopalakrishnan D; Shankar SR; Vasandan AB
    PLoS One; 2010 Feb; 5(2):e9016. PubMed ID: 20126406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory effects of bone marrow-derived mesenchymal stem cells on pro-inflammatory cytokine-stimulated human corneal epithelial cells.
    Wen L; Zhu M; Madigan MC; You J; King NJ; Billson FA; McClellan K; Sutton G; Petsoglou C
    PLoS One; 2014; 9(7):e101841. PubMed ID: 25003339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GVHD-derived plasma as a priming strategy of mesenchymal stem cells.
    Silva-Carvalho AÉ; Rodrigues LP; Schiavinato JL; Alborghetti MR; Bettarello G; Simões BP; Neves FAR; Panepucci RA; de Carvalho JL; Saldanha-Araujo F
    Stem Cell Res Ther; 2020 Apr; 11(1):156. PubMed ID: 32299501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic analysis and functional validation reveal distinct therapeutic capabilities related to priming of mesenchymal stromal/stem cells with IFN-γ and hypoxia: potential implications for their clinical use.
    Calligaris M; Zito G; Busà R; Bulati M; Iannolo G; Gallo A; Carreca AP; Cuscino N; Castelbuono S; Carcione C; Centi C; Amico G; Bertani A; Chinnici CM; Conaldi PG; Scilabra SD; Miceli V
    Front Cell Dev Biol; 2024; 12():1385712. PubMed ID: 38882056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of IL-1β and LPS as optimal activators of monolayer and alginate-encapsulated mesenchymal stromal cell immunomodulation using design of experiments and statistical methods.
    Gray A; Maguire T; Schloss R; Yarmush ML
    Biotechnol Prog; 2015; 31(4):1058-70. PubMed ID: 25958832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TNF-α and IL-1β sensitize human MSC for IFN-γ signaling and enhance neutrophil recruitment.
    Hackel A; Aksamit A; Bruderek K; Lang S; Brandau S
    Eur J Immunol; 2021 Feb; 51(2):319-330. PubMed ID: 32845509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymoproteasome-Expressing Mesenchymal Stromal Cells Confer Protective Anti-Tumor Immunity
    Bikorimana JP; El-Hachem N; El-Kadiry AE; Abusarah J; Salame N; Shammaa R; Rafei M
    Front Immunol; 2020; 11():596303. PubMed ID: 33542714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cell transcriptome analysis reveals the effectiveness of cytokine priming irrespective of heterogeneity in mesenchymal stromal cells.
    Wan Z; Chen YF; Pan Q; Wang Y; Yuan S; Chin HY; Wu HH; Lin WT; Cheng PY; Yang YJ; Wang YF; Kumta SM; Lee CW; Lee OK
    Cytotherapy; 2023 Nov; 25(11):1155-1166. PubMed ID: 37715776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions.
    Kol A; Foutouhi S; Walker NJ; Kong NT; Weimer BC; Borjesson DL
    Stem Cells Dev; 2014 Aug; 23(16):1831-43. PubMed ID: 24803072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin/collagen surface coatings modulate the growth, secretome, and morphology of human mesenchymal stromal cell response to interferon-gamma.
    Cifuentes SJ; Priyadarshani P; Castilla-Casadiego DA; Mortensen LJ; Almodóvar J; Domenech M
    J Biomed Mater Res A; 2021 Jun; 109(6):951-965. PubMed ID: 32786025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microenvironmental cues enhance mesenchymal stem cell-mediated immunomodulation and regulatory T-cell expansion.
    Kadle RL; Abdou SA; Villarreal-Ponce AP; Soares MA; Sultan DL; David JA; Massie J; Rifkin WJ; Rabbani P; Ceradini DJ
    PLoS One; 2018; 13(3):e0193178. PubMed ID: 29513756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancing Mesenchymal Stromal Cell Potency: Inflammatory Licensing
    Skibber MA; Olson SD; Prabhakara KS; Gill BS; Cox CS
    Front Immunol; 2022; 13():874698. PubMed ID: 35874742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases.
    Mebarki M; Iglicki N; Marigny C; Abadie C; Nicolet C; Churlaud G; Maheux C; Boucher H; Monsel A; Menasché P; Larghero J; Faivre L; Cras A
    Stem Cell Res Ther; 2021 Nov; 12(1):571. PubMed ID: 34774107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of type 2 diabetes mellitus on the immunoregulatory characteristics of adipose tissue-derived mesenchymal stem cells.
    Abu-Shahba N; Mahmoud M; El-Erian AM; Husseiny MI; Nour-Eldeen G; Helwa I; Amr K; ElHefnawi M; Othman AI; Ibrahim SA; Azmy O
    Int J Biochem Cell Biol; 2021 Nov; 140():106072. PubMed ID: 34455058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.